MX2020006072A - Métodos y composiciones relacionados con cpf1 para la edición genica. - Google Patents
Métodos y composiciones relacionados con cpf1 para la edición genica.Info
- Publication number
- MX2020006072A MX2020006072A MX2020006072A MX2020006072A MX2020006072A MX 2020006072 A MX2020006072 A MX 2020006072A MX 2020006072 A MX2020006072 A MX 2020006072A MX 2020006072 A MX2020006072 A MX 2020006072A MX 2020006072 A MX2020006072 A MX 2020006072A
- Authority
- MX
- Mexico
- Prior art keywords
- cpf1
- compositions
- related methods
- gene editing
- editing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000010362 genome editing Methods 0.000 title 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 238000010443 CRISPR/Cpf1 gene editing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente divulgación se refiere a métodos y componentes relacionados con CRISPR/Cpf1 para editar una secuencia de ácido nucleico diana, y/o modular la expresión de una secuencia de ácido nucleico diana, así como a métodos y composiciones para evaluar dicha edición y/o modulación de la expresión.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762597118P | 2017-12-11 | 2017-12-11 | |
US201862623501P | 2018-01-29 | 2018-01-29 | |
US201862664905P | 2018-04-30 | 2018-04-30 | |
US201862746494P | 2018-10-16 | 2018-10-16 | |
PCT/US2018/065032 WO2019118516A1 (en) | 2017-12-11 | 2018-12-11 | Cpf1-related methods and compositions for gene editing |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006072A true MX2020006072A (es) | 2020-08-24 |
Family
ID=65023985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006072A MX2020006072A (es) | 2017-12-11 | 2018-12-11 | Métodos y composiciones relacionados con cpf1 para la edición genica. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200299661A1 (es) |
EP (1) | EP3724326A1 (es) |
JP (2) | JP2021505187A (es) |
KR (1) | KR20200097760A (es) |
CN (1) | CN111712569A (es) |
AU (1) | AU2018383712A1 (es) |
CA (1) | CA3085338A1 (es) |
MX (1) | MX2020006072A (es) |
WO (1) | WO2019118516A1 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
US20200216825A1 (en) * | 2019-01-08 | 2020-07-09 | Integrated Dna Technologies, Inc. | CAS12a MUTANT GENES AND POLYPEPTIDES ENCODED BY SAME |
CN116497067A (zh) | 2019-02-13 | 2023-07-28 | 比姆医疗股份有限公司 | 治疗血红素病变的组合物和方法 |
EP4047087A4 (en) * | 2019-08-19 | 2023-08-23 | Southern Medical University | CONSTRUCTION AND APPLICATION OF HIGH-FIDELITY CRISPR/ASCPF1 MUTANTS |
KR20220070456A (ko) * | 2019-09-09 | 2022-05-31 | 스크라이브 테라퓨틱스 인크. | 면역치료법에 사용하기 위한 조성물 및 방법 |
CA3157344A1 (en) * | 2019-11-20 | 2021-05-27 | Cartherics Pty. Ltd. | Method for providing immune cells with enhanced function |
CN111647618A (zh) * | 2020-01-15 | 2020-09-11 | 温州医科大学 | 一种新型基因组编辑工具(Lb2Cas12a-RVR)及其构建方法和应用方法 |
CN113355389B (zh) * | 2020-03-05 | 2022-11-15 | 广西扬翔股份有限公司 | 利用CRISPR/Cas12a系统靶向富集核酸目标区域的方法及其应用 |
KR102497690B1 (ko) * | 2020-09-22 | 2023-02-10 | (주)지플러스생명과학 | 신규한 crispr 연관 단백질 및 이의 용도 |
WO2022065867A1 (ko) * | 2020-09-22 | 2022-03-31 | (주)지플러스생명과학 | 변형된 cas12a 단백질 및 이의 용도 |
JP2023549080A (ja) * | 2020-10-30 | 2023-11-22 | アーバー バイオテクノロジーズ, インコーポレイテッド | Bcl11aを標的とするrnaガイドを含む組成物及びその使用 |
JP2023548588A (ja) * | 2020-10-30 | 2023-11-17 | アーバー バイオテクノロジーズ, インコーポレイテッド | Tracを標的とするrnaガイドを含む組成物及びその使用 |
KR20230093328A (ko) * | 2020-10-30 | 2023-06-27 | 아버 바이오테크놀로지스, 인크. | B2m을 표적화하는 rna 가이드를 포함하는 조성물 및 이의 용도 |
KR20230107292A (ko) * | 2020-11-11 | 2023-07-14 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 다중 후성유전체 편집 |
TW202237826A (zh) | 2020-11-30 | 2022-10-01 | 瑞士商克里斯珀醫療股份公司 | 基因編輯的自然殺手細胞 |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
WO2022125982A1 (en) * | 2020-12-11 | 2022-06-16 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class ii in a cell |
KR20230135068A (ko) * | 2020-12-23 | 2023-09-22 | 인텔리아 테라퓨틱스, 인크. | 세포에서 ciita를 유전적으로 변형시키기 위한 조성물및 방법 |
WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
CN112725487A (zh) * | 2021-02-03 | 2021-04-30 | 张国良 | 用于链霉素耐药结核分枝杆菌的核酸快速检测试剂盒及其检测方法 |
US20240200059A1 (en) | 2021-04-09 | 2024-06-20 | Vor Biopharma Inc. | Photocleavable guide rnas and methods of use thereof |
CA3218053A1 (en) * | 2021-05-06 | 2022-11-10 | Artisan Development Labs, Inc. | Modified nucleases |
WO2022269393A1 (en) * | 2021-06-23 | 2022-12-29 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
WO2023004411A1 (en) * | 2021-07-23 | 2023-01-26 | Icahn School Of Medicine At Mount Sinai | A method for in vivo gene therapy to cure scd without myeloablative toxicity |
CA3228272A1 (en) | 2021-08-02 | 2023-02-09 | Vor Biopharma Inc. | Compositions and methods for gene modification |
WO2023049926A2 (en) | 2021-09-27 | 2023-03-30 | Vor Biopharma Inc. | Fusion polypeptides for genetic editing and methods of use thereof |
WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
CN116144631B (zh) * | 2023-01-17 | 2023-09-15 | 华中农业大学 | 耐热型核酸内切酶及其介导的基因编辑系统 |
CN116179513B (zh) * | 2023-03-10 | 2023-12-22 | 之江实验室 | 一种Cpf1蛋白及其在基因编辑中的应用 |
CN116179511B (zh) * | 2023-03-10 | 2023-12-22 | 之江实验室 | Cpf1蛋白在制备用于核酸检测的试剂盒中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994627A (en) | 1995-03-31 | 1999-11-30 | Common Wealth Scientific And Industrial Research Organisation | Genetic sequences conferring nematode resistance in plants and uses therefor |
GB201013153D0 (en) | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
CN104471067B (zh) | 2012-05-07 | 2020-08-14 | 桑格摩生物治疗股份有限公司 | 用于核酸酶介导的转基因靶向整合的方法和组合物 |
AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
WO2015138510A1 (en) | 2014-03-10 | 2015-09-17 | Editas Medicine., Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
US11680268B2 (en) | 2014-11-07 | 2023-06-20 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
US20190233814A1 (en) * | 2015-12-18 | 2019-08-01 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2017152015A1 (en) * | 2016-03-04 | 2017-09-08 | Editas Medicine, Inc. | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
CN117821458A (zh) * | 2016-03-14 | 2024-04-05 | 爱迪塔斯医药公司 | 用于治疗β-血红蛋白病的CRISPR/CAS相关方法和组合物 |
SG10202010261YA (en) * | 2016-04-18 | 2020-11-27 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
KR102670601B1 (ko) * | 2016-04-19 | 2024-05-29 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
WO2017189308A1 (en) * | 2016-04-19 | 2017-11-02 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2019014564A1 (en) * | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
-
2018
- 2018-12-11 KR KR1020207019710A patent/KR20200097760A/ko not_active Application Discontinuation
- 2018-12-11 CN CN201880089010.3A patent/CN111712569A/zh active Pending
- 2018-12-11 CA CA3085338A patent/CA3085338A1/en active Pending
- 2018-12-11 AU AU2018383712A patent/AU2018383712A1/en active Pending
- 2018-12-11 WO PCT/US2018/065032 patent/WO2019118516A1/en unknown
- 2018-12-11 JP JP2020531964A patent/JP2021505187A/ja active Pending
- 2018-12-11 EP EP18834094.7A patent/EP3724326A1/en active Pending
- 2018-12-11 MX MX2020006072A patent/MX2020006072A/es unknown
-
2020
- 2020-06-11 US US16/899,302 patent/US20200299661A1/en active Pending
-
2023
- 2023-11-13 JP JP2023193282A patent/JP2024023294A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019118516A1 (en) | 2019-06-20 |
AU2018383712A1 (en) | 2020-07-02 |
JP2021505187A (ja) | 2021-02-18 |
EP3724326A1 (en) | 2020-10-21 |
KR20200097760A (ko) | 2020-08-19 |
CA3085338A1 (en) | 2019-06-20 |
US20200299661A1 (en) | 2020-09-24 |
CN111712569A (zh) | 2020-09-25 |
JP2024023294A (ja) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006072A (es) | Métodos y composiciones relacionados con cpf1 para la edición genica. | |
AU2018320870A1 (en) | RNA targeting methods and compositions | |
PH12019500540A1 (en) | Anti-pd-1 antibodies and their uses | |
MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
PH12018501159A1 (en) | Composition and methods for immunooncology | |
MX2017010746A (es) | Composicion y metodos para la expresion regulada de un complejo de arn guia/endonucleasa cas. | |
SG10201809312QA (en) | Nucleic acid synthesis techniques | |
BR112018076190A2 (pt) | ortólogos e sistemas crispr tipo vi | |
PH12018502456A1 (en) | Anti-cd04 antibodies and their uses | |
MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
MY198059A (en) | Anti-ox40 antibodies and their uses | |
WO2015112896A3 (en) | Methods and compositions for sequences guiding cas9 targeting | |
MX2018005392A (es) | Acidos nucleicos modificados dirigidos a acidos nucleicos. | |
MY192561A (en) | Taurine supplemented cell culture medium and methods of use | |
WO2018094356A3 (en) | Compositions and methods for target nucleic acid modification | |
MY192824A (en) | Compound targeting il-23a and tnf-alpha and uses thereof | |
PH12019502171A1 (en) | Composition and methods for immunooncology | |
EP4112611A3 (en) | Modulators of sestrin-gator2 interaction and uses thereof | |
WO2020030984A3 (en) | Compositions and methods for genome engineering with cas12a proteins | |
PH12017501503B1 (en) | Acid composition based on leonardite and amino acids | |
PH12018502233A1 (en) | ErbB INHIBITORS AND USES THEREOF | |
MY195399A (en) | Mixed Decyl Mercaptans Compositions and Methods Of Making Same | |
PH12018500151A1 (en) | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof | |
PH12019501977A1 (en) | Additive composition for ground improvement | |
WO2016050510A3 (en) | Methods and means for increasing stress tolerance and biomass in plants |